人工心脏厂商竞速科创板

Core Insights - Two companies, Suzhou Tongxin Medical Technology Co., Ltd. and Shenzhen Core Medical Technology Co., Ltd., are currently in the IPO queue on the Sci-Tech Innovation Board, focusing on artificial heart development [1][3] - Both companies have not yet achieved profitability but are seeking market recognition with different product strategies [1][3] - The artificial heart market in China is still in its early development stage, lacking a mature competitive landscape [1][3] Company Summaries - Core Medical has five implantable and six interventional artificial heart products in development, with one implantable product already commercialized and two interventional products in the registration phase [3] - Tongxin Medical's first implantable full magnetic levitation left ventricular assist device (CH-VAD) has been approved for sale in China, marking it as the first of its kind in the country [3] - Core Medical aims to raise 1.217 billion yuan through its IPO for various projects, while Tongxin Medical plans to raise 1.064 billion yuan for its own initiatives [4] Financial Performance - Core Medical's revenue for 2022-2025 shows a growth trajectory, with figures of approximately 0, 16.55 million, 93.69 million, and 70.48 million yuan, but it has incurred significant net losses [8] - Tongxin Medical's revenue for the same period is approximately 0.861 million, 5.045 million, 7.735 million, and 7.207 million yuan, also reflecting net losses [8] - Both companies have experienced a decline in the average selling price of their core products during the reporting period [5][6] Market Dynamics - The pricing strategy of both companies aims to expand market share and establish a solid customer base, despite short-term profit compression [7] - The domestic artificial heart market is still developing, with significant challenges in market education and patient awareness [7] - Core Medical is working on its Cor-Vad series, which is in the registration phase and aims to be the first interventional artificial heart product approved in China [7] Industry Outlook - The rush to IPO among artificial heart manufacturers is seen as a necessary step for early commercialization in the industry [4] - The potential for growth in the domestic artificial heart sector is substantial, supported by demand, policy, and technological advancements [10] - Long-term sustainability will depend on technological innovation and cost control, despite the current competitive pricing environment [10]